...Okay. Welcome everyone. I hope everyone can hear me. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi down in Tribeca in Manhattan. It's my pleasure to have with me for the first day of our virtual oncology summit, the leadership team from Syndax Pharmaceuticals, Michael Metzger, the CEO, and Neil Gallagher, President, Head of R&D. So, thank you both so much for taking the time to chat for about one hour on your pipeline and on your, burgeoning set of FDA approvals. I think they're two, as I last counted. So Michael, maybe just to set the scene, just give us a quick rundown of where you are, where the business is. What are the key priorities for 2025 and beyond perhaps. I mentioned the two approvals, so of course we're going to talk about those, but let's just set the scene and then we can dig into some more specifics on the launches for both products. Thanks. Michael Metzger ...
